المؤلفون: Morand E.F., Santos L.L.

مصطلحات الفهرس: nitric oxide, macrophage, nonhuman, review, rheumatoid arthritis/et [Etiology], signal transduction, synovial fluid, T lymphocyte, B7 antigen/ec [Endogenous Compound], CD3 antibody/ec [Endogenous Compound], CD40 antigen/ec [Endogenous Compound], CD86 antigen/ec [Endogenous Compound], cyclooxygenase 2/ec [Endogenous Compound], cytokine, endotoxin, exotoxin, gamma interferon/ec [Endogenous Compound], glucocorticoid, immunoglobulin enhancer binding protein/ec [Endogenous Compound], intercellular adhesion molecule 1/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 2/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], lipopolysaccharide, macrophage migration inhibition factor/ec [Endogenous Compound], macrophage migration inhibition factor/pd [Pharmacology], matrix metalloproteinase/ec [Endogenous Compound], messenger RNA/ec [Endogenous Compound], phospholipase A2/ec [Endogenous Compound], protein p53/ec [Endogenous Compound], recombinant cytokine/pd [Pharmacology], tumor necrosis factor/ec [Endogenous Compound], apoptosis, cell hyperplasia, cell proliferation, disease activity, disease severity, drug inhibition, drug mechanism, human, immune response, in vitro study, innate immunity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32114
Click here for full text options
LibKey Link

المؤلفون: Smith G.M., Brennecke S.P., Scott K.F., Bishop G.J., Rajkovic I.A., Rice G.E.

مصطلحات الفهرس: blood level, article, female, human, labor, maternal blood, pregnancy, phospholipase A2/ec [Endogenous Compound], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/34496
Click here for full text options
LibKey Link

المؤلفون: Morand E.F., Santos L.L.

مصطلحات الفهرس: nitric oxide, macrophage, nonhuman, review, rheumatoid arthritis/et [Etiology], signal transduction, synovial fluid, T lymphocyte, B7 antigen/ec [Endogenous Compound], CD3 antibody/ec [Endogenous Compound], CD40 antigen/ec [Endogenous Compound], CD86 antigen/ec [Endogenous Compound], cyclooxygenase 2/ec [Endogenous Compound], cytokine, endotoxin, exotoxin, gamma interferon/ec [Endogenous Compound], glucocorticoid, immunoglobulin enhancer binding protein/ec [Endogenous Compound], intercellular adhesion molecule 1/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 2/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], lipopolysaccharide, macrophage migration inhibition factor/ec [Endogenous Compound], macrophage migration inhibition factor/pd [Pharmacology], matrix metalloproteinase/ec [Endogenous Compound], messenger RNA/ec [Endogenous Compound], phospholipase A2/ec [Endogenous Compound], protein p53/ec [Endogenous Compound], recombinant cytokine/pd [Pharmacology], tumor necrosis factor/ec [Endogenous Compound], apoptosis, cell hyperplasia, cell proliferation, disease activity, disease severity, drug inhibition, drug mechanism, human, immune response, in vitro study, innate immunity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32114
LibKey Link

المؤلفون: Smith G.M., Brennecke S.P., Scott K.F., Bishop G.J., Rajkovic I.A., Rice G.E.

مصطلحات الفهرس: blood level, article, female, human, labor, maternal blood, pregnancy, phospholipase A2/ec [Endogenous Compound], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/34496
LibKey Link

المؤلفون: Morand E.F., Littlejohn G.O.

مصطلحات الفهرس: antirheumatic agent/pd [Pharmacology], biochemical marker/ec [Endogenous Compound], bisphosphonic acid derivative/cb [Drug Combination], bisphosphonic acid derivative/dt [Drug Therapy], chimeric antibody/dt [Drug Therapy], backache, bone turnover, breast cancer/dt [Drug Therapy], breast cancer/pc [Prevention], cardiovascular disease/si [Side Effect], clinical trial, cost effectiveness analysis, densitometry, diagnostic accuracy, diagnostic imaging, disease course, disease severity, dose response, fracture/co [Complication], fracture/dt [Drug Therapy], fracture/pc [Prevention], gastrointestinal symptom/si [Side Effect], health care cost, hormone substitution, human, incidence, kidney disease/si [Side Effect], knee osteoarthritis, lipid blood level, musculoskeletal disease/di [Diagnosis], musculoskeletal disease/dm [Disease Management], musculoskeletal disease/dt [Drug Therapy], musculoskeletal disease/pc [Prevention], nuclear magnetic resonance imaging, osteoarthritis/di [Diagnosis], osteoarthritis/dm [Disease Management], osteoarthritis/dt [Drug Therapy], osteoarthritis/pc [Prevention], osteoporosis/dm [Disease Management], osteoporosis/dt [Drug Therapy], osteoporosis/pc [Prevention], osteoporosis/si [Side Effect], patient monitoring, physical disability/co [Complication], physical disability/dt [Drug Therapy], physical disability/pc [Prevention], rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dm [Disease Management], rheumatoid arthritis/dt [Drug Therapy], rheumatoid arthritis/pc [Prevention], short survey, chimeric antibody/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/cb [Drug Combination], cyclooxygenase 2 inhibitor/ae [Adverse Drug Reaction], cyclooxygenase 2 inhibitor/cm [Drug Comparison], cyclooxygenase 2 inhibitor/dt [Drug Therapy], cyclooxygenase 2 inhibitor/pd [Pharmacology], cyclosporin/ae [Adverse Drug Reaction], cyclosporin/cb [Drug Combination], cyclosporin/dt [Drug Therapy], cyclosporin/pd [Pharmacology], etanercept/dt [Drug Therapy], etanercept/pd [Pharmacology], glucosamine/dt [Drug Therapy], glucosamine/pd [Pharmacology], immunomodulating agent/ct [Clinical Trial], immunomodulating agent/dt [Drug Therapy], infliximab/dt [Drug Therapy], infliximab/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], leflunomide/pd [Pharmacology], lipid/ec [Endogenous Compound], methotrexate/cb [Drug Combination], methotrexate/do [Drug Dose], osteoprotegerin/dt [Drug Therapy], osteoprotegerin/pd [Pharmacology], parathyroid hormone/dt [Drug Therapy], phospholipase A2/ec [Endogenous Compound], phospholipase A2 inhibitor/ae [Adverse Drug Reaction], phospholipase A2 inhibitor/dt [Drug Therapy], phospholipase A2 inhibitor/pd [Pharmacology], proteoglycan/ec [Endogenous Compound], pyrimidine antagonist/cb [Drug Combination], pyrimidine antagonist/dt [Drug Therapy], pyrimidine antagonist/pd [Pharmacology], raloxifene/dt [Drug Therapy], recombinant interleukin 1 receptor blocking agent/dt [Drug Therapy], recombinant interleukin 1 receptor blocking agent/pd [Pharmacology], risedronic acid/dt [Drug Therapy], selective estrogen receptor modulator/dt [Drug Therapy], tumor necrosis factor/ec [Endogenous Compound], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/pd [Pharmacology], unclassified drug, unindexed drug, adalimumab/dt [Drug Therapy], adalimumab/pd [Pharmacology], drug potency, treatment planning, workplace, alendronic acid/dt [Drug Therapy], antirheumatic agent/ae [Adverse Drug Reaction], antirheumatic agent/ct [Clinical Trial], methotrexate/dt [Drug Therapy], antirheumatic agent/cb [Drug Combination], antirheumatic agent/cm [Drug Comparison], antirheumatic agent/do [Drug Dose], antirheumatic agent/dt [Drug Therapy], antirheumatic agent/po [Oral Drug Administration], antirheumatic agent/pe [Pharmacoeconomics], Short Survey

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32952
Medical Journal of Australia
Click here for full text options
LibKey Link

المؤلفون: Morand E.F., Littlejohn G.O.

مصطلحات الفهرس: antirheumatic agent/pd [Pharmacology], biochemical marker/ec [Endogenous Compound], bisphosphonic acid derivative/cb [Drug Combination], bisphosphonic acid derivative/dt [Drug Therapy], chimeric antibody/dt [Drug Therapy], backache, bone turnover, breast cancer/dt [Drug Therapy], breast cancer/pc [Prevention], cardiovascular disease/si [Side Effect], clinical trial, cost effectiveness analysis, densitometry, diagnostic accuracy, diagnostic imaging, disease course, disease severity, dose response, fracture/co [Complication], fracture/dt [Drug Therapy], fracture/pc [Prevention], gastrointestinal symptom/si [Side Effect], health care cost, hormone substitution, human, incidence, kidney disease/si [Side Effect], knee osteoarthritis, lipid blood level, musculoskeletal disease/di [Diagnosis], musculoskeletal disease/dm [Disease Management], musculoskeletal disease/dt [Drug Therapy], musculoskeletal disease/pc [Prevention], nuclear magnetic resonance imaging, osteoarthritis/di [Diagnosis], osteoarthritis/dm [Disease Management], osteoarthritis/dt [Drug Therapy], osteoarthritis/pc [Prevention], osteoporosis/dm [Disease Management], osteoporosis/dt [Drug Therapy], osteoporosis/pc [Prevention], osteoporosis/si [Side Effect], patient monitoring, physical disability/co [Complication], physical disability/dt [Drug Therapy], physical disability/pc [Prevention], rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dm [Disease Management], rheumatoid arthritis/dt [Drug Therapy], rheumatoid arthritis/pc [Prevention], short survey, chimeric antibody/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/cb [Drug Combination], cyclooxygenase 2 inhibitor/ae [Adverse Drug Reaction], cyclooxygenase 2 inhibitor/cm [Drug Comparison], cyclooxygenase 2 inhibitor/dt [Drug Therapy], cyclooxygenase 2 inhibitor/pd [Pharmacology], cyclosporin/ae [Adverse Drug Reaction], cyclosporin/cb [Drug Combination], cyclosporin/dt [Drug Therapy], cyclosporin/pd [Pharmacology], etanercept/dt [Drug Therapy], etanercept/pd [Pharmacology], glucosamine/dt [Drug Therapy], glucosamine/pd [Pharmacology], immunomodulating agent/ct [Clinical Trial], immunomodulating agent/dt [Drug Therapy], infliximab/dt [Drug Therapy], infliximab/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], leflunomide/pd [Pharmacology], lipid/ec [Endogenous Compound], methotrexate/cb [Drug Combination], methotrexate/do [Drug Dose], osteoprotegerin/dt [Drug Therapy], osteoprotegerin/pd [Pharmacology], parathyroid hormone/dt [Drug Therapy], phospholipase A2/ec [Endogenous Compound], phospholipase A2 inhibitor/ae [Adverse Drug Reaction], phospholipase A2 inhibitor/dt [Drug Therapy], phospholipase A2 inhibitor/pd [Pharmacology], proteoglycan/ec [Endogenous Compound], pyrimidine antagonist/cb [Drug Combination], pyrimidine antagonist/dt [Drug Therapy], pyrimidine antagonist/pd [Pharmacology], raloxifene/dt [Drug Therapy], recombinant interleukin 1 receptor blocking agent/dt [Drug Therapy], recombinant interleukin 1 receptor blocking agent/pd [Pharmacology], risedronic acid/dt [Drug Therapy], selective estrogen receptor modulator/dt [Drug Therapy], tumor necrosis factor/ec [Endogenous Compound], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/pd [Pharmacology], unclassified drug, unindexed drug, adalimumab/dt [Drug Therapy], adalimumab/pd [Pharmacology], drug potency, treatment planning, workplace, alendronic acid/dt [Drug Therapy], antirheumatic agent/ae [Adverse Drug Reaction], antirheumatic agent/ct [Clinical Trial], methotrexate/dt [Drug Therapy], antirheumatic agent/cb [Drug Combination], antirheumatic agent/cm [Drug Comparison], antirheumatic agent/do [Drug Dose], antirheumatic agent/dt [Drug Therapy], antirheumatic agent/po [Oral Drug Administration], antirheumatic agent/pe [Pharmacoeconomics], Short Survey

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32952
Medical Journal of Australia
LibKey Link